Literature DB >> 17689241

Progesterone regulates catechol-O-methyl transferase gene expression in breast cancer cells: distinct effect of progesterone receptor isoforms.

Salama A Salama1, Mohammad Jamaluddin, Raj Kumar, Memy H Hassan, Ayman Al-Hendy.   

Abstract

There is strong evidence that catechol-O-methyl transferase (COMT) protects breast cells against estrogen-induced cancer by detoxifying catecholestrogens, the carcinogenic estrogen metabolites. COMT gene expression is controlled by two promoters - a proximal promoter (COMTP1) and a distal promoter (COMTP2) - that regulate the expression of soluble (S-COMT) and membrane-bound (MB-COMT) isoforms, respectively. We investigated the transcriptional regulation of the COMT gene by progesterone/progesterone receptors in breast cancer cells. Our results indicated that progesterone (P4) downregulates COMT gene expression in breast cancer cell lines. In addition, the COMTP1 and COMTP2 harbor several progesterone response elements (PREs). Electrophoretic mobility shift assay (EMSA) indicated that nuclear extracts of T47D cells bind to the identified PREs in COMTP1. Site-directed mutagenesis of PREs in COMTP1 not only reversed the P4-induced inhibition of COMTP1, but also increased its basal activity. The two progesterone receptor isoforms, PR-A and PR-B, were found to have opposite effects on the regulation of P4 in COMT expression; PR-A is associated with P4-induced upregulation of COMT, while PR-B is associated with P4-induced downregulation of COMT. In summary, our data demonstrated that P4 downregulates the COMT gene expression through multiple PREs in the COMT promoters and that different progesterone receptor isoforms have distinctive effects on COMT gene expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17689241      PMCID: PMC2254140          DOI: 10.1016/j.jsbmb.2007.03.049

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  41 in total

1.  Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells.

Authors:  Jennifer K Richer; Britta M Jacobsen; Nicole G Manning; M Greg Abel; Douglas M Wolf; Kathryn B Horwitz
Journal:  J Biol Chem       Date:  2001-11-20       Impact factor: 5.157

2.  Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism.

Authors:  J J Li; S A Li
Journal:  Fed Proc       Date:  1987-04

3.  Carcinogenicity of catechol estrogens in Syrian hamsters.

Authors:  J G Liehr; W F Fang; D A Sirbasku; A Ari-Ulubelen
Journal:  J Steroid Biochem       Date:  1986-01       Impact factor: 4.292

4.  Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form.

Authors:  B Bertocci; V Miggiano; M Da Prada; Z Dembic; H W Lahm; P Malherbe
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

5.  Medical hypothesis: hyperhomocysteinemia is a risk factor for estrogen-induced hormonal cancer.

Authors:  Bao Ting Zhu
Journal:  Int J Oncol       Date:  2003-03       Impact factor: 5.650

Review 6.  Expression profiling of human breast cancers and gene regulation by progesterone receptors.

Authors:  Britta M Jacobsen; Jennifer K Richer; Carol A Sartorius; Kathryn B Horwitz
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-07       Impact factor: 2.673

7.  Progesterone receptors A and B differentially modulate corticotropin-releasing hormone gene expression through a cAMP regulatory element.

Authors:  X Ni; Y Hou; R Yang; X Tang; R Smith; R C Nicholson
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

8.  Human catechol-O-methyltransferase down-regulation by estradiol.

Authors:  H Jiang; T Xie; D B Ramsden; S L Ho
Journal:  Neuropharmacology       Date:  2003-12       Impact factor: 5.250

9.  Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function.

Authors:  E Vegeto; M M Shahbaz; D X Wen; M E Goldman; B W O'Malley; D P McDonnell
Journal:  Mol Endocrinol       Date:  1993-10

10.  Breast cancer and hormone-replacement therapy in the Million Women Study.

Authors:  Valerie Beral
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

View more
  6 in total

Review 1.  Progesterone receptors, their isoforms and progesterone regulated transcription.

Authors:  Britta M Jacobsen; Kathryn B Horwitz
Journal:  Mol Cell Endocrinol       Date:  2011-09-17       Impact factor: 4.102

2.  Network analysis of the genomic basis of the placebo effect.

Authors:  Rui-Sheng Wang; Kathryn T Hall; Franco Giulianini; Dani Passow; Ted J Kaptchuk; Joseph Loscalzo
Journal:  JCI Insight       Date:  2017-06-02

3.  Towards non-surgical therapy for uterine fibroids: catechol-O-methyl transferase inhibitor shrinks uterine fibroid lesions in the Eker rat model.

Authors:  M H Hassan; H Fouad; S Bahashwan; A Al-Hendy
Journal:  Hum Reprod       Date:  2011-09-06       Impact factor: 6.918

4.  Effect of tumor necrosis factor-alpha on estrogen metabolism and endometrial cells: potential physiological and pathological relevance.

Authors:  Salama A Salama; Marwa W Kamel; Concepcion R Diaz-Arrastia; Xia Xu; Timothy D Veenstra; Sana Salih; Shaleen K Botting; Raj Kumar
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

5.  Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model.

Authors:  Memy H Hassan; Salama A Salama; Dong Zhang; Hossam M M Arafa; Farid M A Hamada; Hala Fouad; Cheryl C Walker; Ayman Al-Hendy
Journal:  Fertil Steril       Date:  2009-01-14       Impact factor: 7.329

6.  Towards fibroid gene therapy: adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model.

Authors:  Memy Hassan; Dong Zhang; Salama Salama; Farid Hamada; Hossam Arafa; Hala Fouad; Cheryl Walker; Ayman Al-Hendy
Journal:  Gynecol Obstet Invest       Date:  2009-03-27       Impact factor: 2.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.